{"entity":{"id":"nct05653453","kind":"trial","name":"Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer","aka":[],"tldr":"A phase 3 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by Jiangsu Healthy Life Innovation Medical Technology Co., Ltd, now recruiting.","summary":"Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer is a phase 3 interventional study registered as NCT05653453 by Jiangsu Healthy Life Innovation Medical Technology Co., Ltd, with 512 participants planned, started 2022-12-20 and due to reach its primary completion in 2026-12-25. Interventions recorded: Tumor treating fields combined with Gemcitabine hydrochloride and albumin binding paclitaxel and Gemcitabine hydrochloride and albumin binding paclitaxel.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05653453","url":"https://clinicaltrials.gov/study/NCT05653453"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["gemcitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05653453","phase":"3","setting":"Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer","sponsor":"Jiangsu Healthy Life Innovation Medical Technology Co., Ltd","enrolled":512,"outcomes":[]},"route":"/trials/nct05653453/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"drug":[{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"}]}}